Slide 1: Earnings call Q2 2023
Devyser Earnings call Q2 2023 August 23, 2023
Slide 2: Today’s presenters
Today’s presenters Fredrik Alpsten Sabina Berlin CEO CFO
Slide 3: The value of correct and fast diagnosis
The value of correct and fast diagnosis Waiting for test results is a stressful experience for patients and their families The outcome can be life-changing
Slide 4: Our mission and vision
Our mission Be the pioneering leader of diagnostic solutions and provide fast, accurate, and easy-to-use solutions to labs worldwide. Our vision A world where personalized medicine is universally available thanks to simplified and reliable genetic tests.
Slide 5: Our diagnostic areas
Our diagnostic areas HEREDITARY DISEASES
Slide 6: Second quarter 2023
Second quarter 2023
Slide 7: EBIT Development (EBIT per quarter)
EBIT Development (EBIT per quarter) MSEK 10 5 0 -5 -10 -15 -20 -25 -30 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 7
Slide 8: Agreement with Thermo Fisher
Agreement with Thermo Fisher · Partnering with Thermo Fisher, the leading innovator in the HLA industry · Exclusive rights to commercialize Devyser’s post-transplant NGS portfolio under combined brand in North America and Europe · Thermo Fisher launched at end of July
Slide 9: US-based clinical testing laboratory
US-based clinical testing laboratory · Clinical Laboratory Improvement Amendments (CLIA) certified by the Centers for Medicare and Medicaid Services (CMS) · State-of-the-art NGS laboratory · Based in Roswell, Atlanta USA Direct access to patients and their physicians to novel laboratory-developed te
Slide 10: Successful product development and registration work (highlights)
Successful product development and registration work (highlights) • Launch of Devyser Accept cfDNA (April) • Launch of two new oncology products, Devyser LynchFAP and Devyser BRCA PALB2 (June) • Devyser RHD regulatory approved as Class III IVD in Canada (May) • One Lambda Devyser Chimerism and One L
Slide 11: Second quarter 2023
Second quarter 2023 Financials - Net sales MSEK 37.7 (30.9) - Sales growth+22% (+13 % in local currency) - Gross margin 83% (80%) - EBIT -13.5 (-12.6) Highlights - Weak April, strong May and June - Agreement with Thermo Fisher - Swecare Export Award - Opening of CLIA-lab and first patient - RHD regu
Slide 12: January – June 2023
January – June 2023 Financials - Net sales MSEK 77.2 (61.3) - Sales growth+26% (17% in local currency) - Gross margin 84% (81%) - EBIT -32.6 (-17.9) Highlights - Launch of Compact, first IVDR approved product 12
Slide 13: LTM July 2022-June 2023
LTM July 2022-June 2023 Financials - Net sales MSEK 142.5 (110.2) - Sales growth +29% - Gross margin 83% (79%) - EBIT -66.0 (-34.3) 13
Slide 14: Quarterly sales growth
Quarterly sales growth 40 90 SEK million Net sales, SEK million Gross margin, % % 35 85 30 80 25 20 75 15 70 10 65 5 0 60 14
Slide 15: Sales per channel
Sales per channel MSEK Q2 2023 Q2 2022 Change, % YTD 2023 YTD 2022 Change, % Direct sales 29.2 23.3 25.3 62.1 45.0 37.9 Distributor sales 8.5 7.6 12.8 15.2 16.2 -6.6 Total 37.7 30.9 22.3 77.2 61.3 26.1
Slide 16: Sales per region
Sales per region MSEK Q2 2023 Q2 2022 Change, % YTD 2023 YTD 2022 Change, % EMEA 33.0 29.1 13.1 69.9 58.3 19.9 APAC 1.4 0.9 47.5 2.7 1.6 75.1 North and South America 3.4 0.8 321.5 4.6 1.4 231.7 Total 37.7 30.9 22.3 77.2 61.3 26.1
Slide 17: Key financials
Key financials MSEK Q2 Q2 Q1-Q2 Q1-Q2 2023 2022 2023 2022 Net sales 37.7 30.9 77.2 61.3 Cost of goods sold -6.3 -6.2 -12.1 -11.4 Gross profit 31.5 24.7 65.1 49.9 Gross margin 83.4 79.9 84.3 81.4 Other operating income 4.7 1.6 5.9 4.3 Selling expenses -30.7 -20.8 -61.5 -40.3 Administrative expenses -
Slide 18: Key financials (cont.)
Key financials (cont.) Q2 Q2 Q1-Q2 Q1-Q2 2023 2022 2023 2022 Cash-flow operating activities, MSEK -22.8 -7.9 -42.1 -15.3 Available liquid funds, MSEK 303.0 400.8 303.0 400.8 Net debt, MSEK -229.6 -382.5 -229.6 -382.5 Avererage No of employees 98 72 96 69
Slide 19: Going forward
Going forward - Continued focus on direct sales markets in Europe - Increased US presence with the CLIA lab and our US commercial partner - Continue our way to profitability 19
Slide 20: Q&A
O&A Dvysr.
Slide 21: Connect with us
Connect with us www.devyser.com